CAMPATH Pages on BioPortfolio:

Biotechnology News CAMPATH Search
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory.
http://www.bioportfolio.co.uk/CAMPATH-news.htm...

Campath Improves Survival of Refractory CLL Patients
Campath demonstrated encouraging data in terms of overall objective ... Campath is indicated for use for the treatment of B-CLL in patients who have failed ...
http://www.bioportfolio.com/news/btech_051502_2.htm...

Biotechnology News FDA EMEA CDER regulatory arzerra. genmab. glaxo ...
Current Search: fda: 13498, emea: 458, cder: 26, regulatori: 6442, arzerra: 78, genmab: 79, glaxo: 544, genco: 8, genzo: 15, campath: 19 ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...

BTG plc: Final Phase II Results of CampathR Multiple Sclerosis ...
23 Oct 2008 ... Results show a significant and sustained reduction in disability and risk of relapse for MS patients on Campath® versus those on Rebif® ...
http://www.bioportfolio.com/biotech_news/BTG_11.htm...

Biotechnology News FLUDARA Search
Genzyme Corporation (Nasdaq: GENZ) announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with ...
http://www.bioportfolio.co.uk/FLUDARA-news.htm...

BioPortfolio Limited Forecast Insight: Multiple Sclerosis ...
Table 36: Multiple sclerosis-specific sales forecast ($m) for alemtuzumab ( Campath) in the seven major markets, 2007-17 96 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_496.html...

BioPortfolio.com - BioWeb Thrombocytopenia Search
Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

...

BioPortfolio.com - BioWeb Lymphopenia Search
FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER Package Insert Campath ® (ALEMTUZUMAB) Millennium and ILEX Partners, ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

The Future of Monoclonal Antibody Therapeutics
Simulect, Zenapax and Campath. 98. Campath. 98. Others. 99. Innovation in antibody engineering. 99. New indications. 100. Challenges. 101. Generic
biologics ...
http://www.bioportfolio.com/cgi-bin/acatalog/The%20Future_of...

Results from other life science and pharmaceutical sites:

Alemtuzumab - Wikipedia, the free encyclopedia
The origins of alemtuzumab date back to Campath-1 which was derived from the ... This became known as Campath-1H and serves as the basis for alemtuzumab. ...
http://en.wikipedia.org/wiki/Alemtuzumab...

Buzz around Campath proof-of-concept trial in MS : Article ...
The next two years are expected to reveal much about not only Campath in MS, ... In the phase 2 trial, known as CAMMS223, Campath was administered once ...
http://www.nature.com/nbt/journal/v27/n1/full/nbt0109-6.html...

Alemtuzumab (marketed as Campath) Information
9 Sep 2009 ... This is a summary of the most important information about Campath. For more information, talk to your healthcare professional. ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol ...
CAMPATH-1 antibodies recognize a unique molecule on human lymphocytes and are unusually efficient at causing cell lysis with homologous complement. ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1134413/...

Bone Marrow Transplantation - In vivo Campath for the prevention ...
1 Nov 2004 ... In vivo Campath for the prevention of GvHD following allogeneic HSCT: effects of dose, schedule and antibody type ...
http://www.nature.com/bmt/journal/v34/n12/full/1704695a.html...

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth ...
The CAMPATH-1H (CD52) antigen is a 21 000-28 000 MW glycopeptide antigen that is highly expressed on T and B lymphocytes and is coupled to the membrane by a ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364410/...

Bone Marrow Transplantation - Successful use of Campath-1H in the ...
At this stage, he was treated with Campath-1H i.v. 10 mg/day on days 1–5 ... Response of liver GvHD to Campath-1H, showing marked improvement in liver ...
http://www.nature.com/bmt/journal/v34/n3/full/1704573a.html...

Mooren's ulcer resolved with campath-1H
Campath-1H is a humanised lymphocytotoxic monoclonal antibody (mAb) that targets the CD52 antigen on T lymphocytes. Successful mAb therapy using campath-1H ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771776/...

Information for Healthcare Professionals - Alemtuzumab (marketed ...
9 Sep 2009 ... Campath is not approved for the treatment of MS. Campath is approved for treating B-cell chronic lymphocytic leukemia (CLL) in patients who ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

CAMPATH: from concept to clinic
CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569536/...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.